Printer Friendly

Caris' studies show Caris Molecular Intelligence service facilitates molecular analysis of lung tumours.

M2 PHARMA-October 30, 2014-Caris' studies show Caris Molecular Intelligence service facilitates molecular analysis of lung tumours

(C)2014 M2 COMMUNICATIONS

30 October 2014 - US personalised medicine specialist Caris Life Sciences unveiled Thursday results from two large trials, showing that its panomic, comprehensive tumour profiling service, Caris Molecular Intelligence, facilitated the molecular analysis of lung tumours.

The biomarker data from the two data sets, disclosed at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology, have potentially significant therapeutic implications for management of patients with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and neuroendocrine tumours (NETs) of the lung, in addition for detecting potential mechanisms of drug resistance.

The trials used Caris Molecular Intelligence's multi-technology approach, which comprised gene sequencing (next-generation [NGS] or Sanger sequencing), protein analysis (immunohistochemistry [IHC]), and gene copy number analysis (chromogenic and fluorescent in situ hybridisation [CISH and FISH]).

Data from the first trial underlined the genomic heterogeneity of SCLC and lung NETs, based on detection of genomic alterations and driver mutations in multiple genes of interest. The second trial investigated concurrent aberrations of NSCLC biomarkers that may account for drug resistance and show potential strategies for combination therapies that may be beneficial for certain patient cohorts.

Caris Life Sciences chief medical officer, Dr. Sandeep Reddy, noted that the trials demonstrate the important utility of comprehensive, multi-platform molecular profiling as a tool to fully characterise and elucidate oncogenic drivers in lung cancers. This is especially relevant since the NCCN guidelines have been updated in 2014 to reflect the need for multiplex testing as the replacement for simply testing EGFR and ALK alone. In both trials, Caris Molecular Intelligence enabled identification of protein, gene copy number, and genetic alterations in lung tumours. This is data that may help personalise treatment strategies for common and relatively rare subtypes of lung cancer, Dr. Reddy noted.

Caris Molecular Intelligence uses various analytical technologies, such as immunohistochemistries, fluorescence and chromogenic in situ hybridisation, polymerase chain reaction and next-generation sequencing, to provide full and clinically relevant profile of a person's unique cancer-related biomarkers. The product also evaluates another biological components including RNA and protein expression levels to help doctors choose the most appropriate therapy for each patient.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 30, 2014
Words:377
Previous Article:Eurofins Genomics, Igenbio combine expertise in sequencing, analysis services for microbial, fungal, algal organisms.
Next Article:Blood test for brain insulin resistance accurately predicts Alzheimer's disease risk, trial shows.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters